Patents by Inventor Kenneth Dobie

Kenneth Dobie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense modulation of superoxide dismutase 1, soluble expression
    Publication number: 20070054869
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
    Type: Application
    Filed: June 7, 2006
    Publication date: March 8, 2007
    Inventors: C. Bennett, Kenneth Dobie, Don Cleveland, Richard Smith
  • Modulation of SOCS-3 expression
    Publication number: 20070021367
    Abstract: Compounds, compositions and methods are provided for modulating the expression of SOCS-3. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SOCS-3. Methods of using these compounds for modulation of SOCS-3 expression and for diagnosis and treatment of disease associated with expression of SOCS-3 are provided.
    Type: Application
    Filed: August 17, 2006
    Publication date: January 25, 2007
    Inventors: Ian Popoff, Susan Freier, Kenneth Dobie
  • Modulation of endothelial lipase expression
    Publication number: 20070020675
    Abstract: Compounds, compositions and methods are provided for modulating the expression of endothelial lipase. The compositions comprise oligonucleotides, targeted to nucleic acid encoding endothelial lipase. Methods of using these compounds for modulation of endothelial lipase expression and for diagnosis and treatment of disease associated with expression of endothelial lipase are provided.
    Type: Application
    Filed: August 9, 2006
    Publication date: January 25, 2007
    Inventor: Kenneth Dobie
  • Modulation of HIF1alpha and HIF2alpha expression
    Publication number: 20070020679
    Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1? and/or HIF2?. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1? and HIF2?. Methods of using these compounds for modulation of HIF1? and/or HIF2? expression and for diagnosis and treatment of disease associated with expression of HIF1? and/or HIF2? are provided.
    Type: Application
    Filed: September 26, 2006
    Publication date: January 25, 2007
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Donna Ward, Kenneth Dobie, Eric Marcusson, Susan Freier
  • Antisense modulation of superoxide dismutase 1, soluble expression
    Publication number: 20060293269
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
    Type: Application
    Filed: June 7, 2006
    Publication date: December 28, 2006
    Inventors: C. Bennett, Kenneth Dobie
  • Modulation of apolipoprotein c-III expression
    Publication number: 20060264395
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided.
    Type: Application
    Filed: April 15, 2004
    Publication date: November 23, 2006
    Inventors: Rosanne Crooke, Mark Graham, Kristina Tarbet, Kenneth Dobie
  • Modulation of HIF1 beta expression
    Publication number: 20060252720
    Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1-beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1-beta. Methods of using these compounds for modulation of HIF1-beta expression and for diagnosis and treatment of diseases and conditions associated with expression of HIF1-beta are provided.
    Type: Application
    Filed: August 25, 2005
    Publication date: November 9, 2006
    Inventors: Eric Marcusson, Scott Henry, Youngsoo Kim, Kenneth Dobie
  • Antisense modulation of superoxide dismutase 1, soluble expression
    Patent number: 7132530
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
    Type: Grant
    Filed: August 4, 2003
    Date of Patent: November 7, 2006
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Kenneth Dobie
  • Compositions and their uses directed to thymus and activation-regulated chemokine (TARC)
    Publication number: 20060234972
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of TARC in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of TARC, airway hyperresponsiveness, and/or pulmonary inflammation.
    Type: Application
    Filed: March 27, 2006
    Publication date: October 19, 2006
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: James Karras, Kenneth Dobie
  • Modulation of growth hormone receptor expression and insulin-like growth factor expression
    Publication number: 20060178325
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Application
    Filed: February 27, 2004
    Publication date: August 10, 2006
    Inventors: George Tachas, Kenneth Dobie, Christopher Belyea, Mark Heffernan, Ravi Jain
  • Modulation of SLC26A2 expression
    Publication number: 20060154885
    Abstract: Compounds, compositions and methods are provided for modulating the expression of SLC26A2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SLC26A2. Methods of using these compounds for modulation of SLC26A2 expression and for diagnosis and treatment of disease associated with expression of SLC26A2 are provided.
    Type: Application
    Filed: March 4, 2005
    Publication date: July 13, 2006
    Inventors: C. Bennett, Brett Monia, Nicholas Dean, Xiaoxing Xu, Sanjay Bhanot, Brenda Baker, Susan Freier, Lex Cowsert, Robert McKay, Muthiah Manoharan, F. Dorr, Jon Holmlund, Alexander Borchers, Vickie Brown-Driver, Jacqueline Wyatt, Shin Flournoy, Elizabeth Ackermann, Hong Zhang, Andrew Watt, Eric Maracusson, Scott Cooper, Erich Koller, Loren Miraglia, William Ricketts, Kenneth Dobie, Tamara Sipes
  • Antisense modulation of MyD88 expression
    Patent number: 7033830
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MyD88. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MyD88. Methods of using these compounds for modulation of MyD88 expression and for treatment of diseases associated with expression of MyD88 are provided.
    Type: Grant
    Filed: September 26, 2003
    Date of Patent: April 25, 2006
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: James Karras, Kenneth Dobie
  • Antisense modulation of matrix metalloproteinase 1 expression
    Publication number: 20060074043
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of matrix metalloproteinase 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding matrix metalloproteinase 1. Methods of using these compounds for modulation of matrix metalloproteinase 1 expression and for treatment of diseases associated with expression of matrix metalloproteinase 1 are provided.
    Type: Application
    Filed: October 13, 2005
    Publication date: April 6, 2006
    Inventors: Brett Monia, Susan Freier, Sanjay Bhanot, Madeline Butler, Andrew Watt, Jacqueline Wyatt, Brenda Baker, Lex Cowsert, Kenneth Dobie
  • Antisense modulation of hematopoietic cell protein tyrosine kinase expression
    Publication number: 20060057570
    Abstract: Antisense compounds compositions and methods are provided for modulating the expression of hematopoietic cell protein tyrosine kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleinc acids encoding hematopoietic cell protein tyrosine kinase. Methods of using these compounds for modulation of hematopoietic cell protein tyrosine kinase expression and for treatment of diseases associated with expression of hematopoietic cell protein tyrosine kinase are provided.
    Type: Application
    Filed: December 4, 2002
    Publication date: March 16, 2006
    Inventors: Alexander Borchers, Kenneth Dobie
  • Modulation of glucocorticoid receptor expression
    Publication number: 20060025373
    Abstract: Compounds, compositions and methods are provided for modulating the expression of glucocorticoid receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucocorticoid receptor. Methods of using these compounds for modulation of glucocorticoid receptor expression and for diagnosis and treatment of diseases and conditions associated with expression of glucocorticoid receptor are provided.
    Type: Application
    Filed: August 18, 2005
    Publication date: February 2, 2006
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Kenneth Dobie, Susan Freier
  • Antisense modulation of PTP1B expression
    Publication number: 20060025372
    Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
    Type: Application
    Filed: August 1, 2005
    Publication date: February 2, 2006
    Inventors: Sanjay Bhanot, Lex Cowsert, Jacqueline Wyatt, Brett Monia, Madelline Butler, Robert McKay, Susan Freier, Kenneth Dobie
  • Antisense modulation of MEKK4 expression
    Publication number: 20060019920
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK4. Methods of using these compounds for modulation of MEKK4 expression and for treatment of diseases associated with expression of MEKK4 are provided.
    Type: Application
    Filed: July 11, 2005
    Publication date: January 26, 2006
    Inventors: C. Bennett, Susan Freier, Brett Monia, Nicholas Dean, Hong Zhang, Robert McKay, Donna Ward, William Gaarde, Jacqueline Wyatt, Andrew Watt, Rosanne Crooke, Mark Graham, Pamela Nero, Kenneth Dobie, Alexander Borchers, Eric Marcusson, Mark Roach
  • Compositions and their uses directed to bone growth modulators
    Publication number: 20060003953
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of a bone growth modulator in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Application
    Filed: December 3, 2004
    Publication date: January 5, 2006
    Inventors: C. Bennett, Madeline Butler, Nicholas Dean, Kenneth Dobie, Joshua Finger, Ravi Jain, Robert McKay, Brett Monia, Kathleen Myers
  • Antisense modulation of ptpn12 expression
    Publication number: 20050282760
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTPN12. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPN12. Methods of using these compounds for modulation of PTPN12 expression and for treatment of diseases associated with expression of PTPN12 are provided.
    Type: Application
    Filed: June 12, 2003
    Publication date: December 22, 2005
    Inventors: Lex Cowsert, Kenneth Dobie
  • Modulation of growth hormone receptor expression and insulin-like growth factor expression
    Publication number: 20050282761
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Application
    Filed: August 25, 2004
    Publication date: December 22, 2005
    Inventors: George Tachas, Kenneth Dobie, Ravi Jain, Christopher Belyea, Mark Heffernan